In the early 1900 s Paul Ehrlich described an ideal drug as a magic bullet. magic bullet. Such a drug would be aimed precisely at a disease site and would.

Slides:



Advertisements
Similar presentations
Warfarin, Insulin and Digoxin are the most Dangerous drugs in the elderly. Do we believe that?
Advertisements

Walsall Healthcare NHS Trust Medicines Management.
Technical Briefing Seminar September |1 | The need for Pharmacovigilance Mary R Couper and Shanthi Pal Quality Assurance and Safety of Medicines.
2.11 Conduct Medication Management University Medical Center Health System Lubbock, TX Jason Mills, PharmD, RPh Assistant Director of Pharmacy.
Pharmacoepidemiology: Goals and Methods Sean Hennessy, PharmD, PhD Assistant Professor of Epidemiology & Pharmacology Center for Clinical Epidemiology.
OPTIMISING MEDICINES USE GRAHAM DAVIES Professor of Clinical Pharmacy & Therapeutics Institute of Pharmaceutical Science King’s College London.
FDA’s MedWatch Program Outreach to Healthcare Professionals and the Public n Managing the Risks of Medical Product Use.
Clinical Pharmacy Basma Y. Kentab MSc..
Clinical pharmacy Dr. Mohammed Al-Rekabi Lecture One First Semester.
Drug safety in the elderly EFNS Stockholm 2012 Barbro Westerholm Prof.em, Member of Swedish Parliament.
An Update on NSAID Labeling and Data Review DSaRM Advisory Committee February 10, 2006 Sharon Hertz, M.D. Deputy Director Division of Anesthesia, Analgesia,
Eureka Pre-Clinical Investigation Animal toxicology Animal pharmacokinetics/ pharmacodynamics Clinical Investigation Phase I Safety and pharmacology Phase.
Testing People Scientifically.  Clinical trials are research studies in which people help doctors and researchers find ways to improve health care. Each.
Responsibilities and Principles of Drug Administration
Adverse Drug Event Reporting
دکتر فرهاد گودرزیان نماینده ADR معاونت غذا وداروی اصفهان
ADVERSE EFFECTS OF DRUGS Phase II May Adverse Drug Reaction An adverse reaction to a drug is a harmful or unintended response. ADRs are claimed.
PHARMACOVIGILANCE AND CLINICAL TRIALS DIVISION 20 August 2015 Victoria Falls Protecting Your Right to Quality Medicines and Medical Devices.
Reproductive Health Drugs, Pregnancy Labeling Subcommittee Meeting March 28-29, 2000 Holli A. Hamilton, M.D., M.P.H. Pregnancy Labeling Team Office of.
INTRODUCTION TO TOXICOLOGY SIDNEY GREEN, PH.D. DEPARTMENT OF PHARMACOLOGY COLLEGE OF MEDICINE HOWARD UNIVERISTY.
Biomedical Research.
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
Problems of Polypharmacy
DEVELOPING EVIDENCE ON VACCINE SAFETY Susan S. Ellenberg, Ph.D. Center for Clinical Epidemiology and Biostatistics U Penn School of Medicine Global Vaccines.
METHODS TO STUDY DRUG SAFETY PROBLEMS animal experiments clinical trials epidemiological methods –spontaneous reporting case reports case series –Post-Marketing.
Definitions. Clinical pharmacy is the branch of Pharmacy where pharmacists provide patient care that optimizes the use of medication and promotes health,
Using Medicines Safely (2:50) Click here to launch video Click here to download print activity.
Technical Briefing Seminar September |1 | Methods to study medicine safety problems Mary R Couper Quality Assurance and Safety of Medicines.
Dr Shanthi Pal Quality Assurance and Safety of Medicines WHO
Drug Safety and Risk Management Advisory Committee May 18-19, Overview of Drug Safety Challenges Gerald J. Dal Pan, MD, MHS Director Division of.
The Dilemma of Diclofenac Injection for the Iranian Health System Authors: Shalviri G, Cheraghali M, Gholami K, Kamali E, Daryabari N Institution: Ministry.
PV of ARVs, November 2009, Dar Es Salaam 1 |1 | The need for Pharmacovigilance Shanthi Pal Quality Assurance and Safety of Medicines.
Preventing Errors in Medicine
Focus on Nursing Pharmacology
Signal identification and development I.Ralph Edwards.
Dr Mary Couper Quality Assurance and Safety of Medicines WHO
Pharmacovigilance WHO definition
Postmarketing Pharmacovigilance Practice at FDA Lanh Green, Pharm.D., M.P.H. Office of Surveillance and Epidemiology June 21, 2006.
European Patients’ Academy on Therapeutic Innovation Introduction to pharmacovigilance Monitoring the safety of medicines.
Applying New Science to Drug Safety Janet Woodcock, M.D. Acting Deputy Commissioner for Operations April 15, 2005.
Epidemiology. Classically speaking Classically speaking EPI DEMO LOGOS Upon,on,befall People,population,man the Study of The study of anything that happens.
Questions to Committee about Potential Cancer Risk with Use of Topical Immunosuppressants (Calcineurin Inhibitors) Question 1: Messages about Risk A. Based.
27 June 2000Victor F. C. Raczkowski, M.D.1 Risk-Management Options Victor F. C. Raczkowski, M.D., M.S. Gastrointestinal Drugs Advisory Committee 27 June.
Viagra (sildenafil citrate): Extensive Clinical and Post-Marketing Experience Michael Sweeney, MD Senior Medical Director Pfizer Inc.
Why do we need Pharmacovigilance?
Copyright © 2016, 2013, 2010 by Saunders, an imprint of Elsevier Inc. All rights reserved. Chapter 3 Drug Regulation, Development, Names, and Information.
Off-label Use.
Documentation of pharmaceutical care
Detection & monitoring of ADR
Why do we need Pharmacovigilance?
World Health Organization
8. Causality assessment:
Prescribing.
3. Key definitions Multi-partner training package on active TB drug safety monitoring and management (aDSM) July 2016.
Introduction to Clinical Pharmacy
Pharmacovigilance Dr. SURENDRA.S.AKASH MD.
عناوین برنامه واهداف ADR ونقش آن در ایمنی دارویی محاسبات دارویی
9. Introduction to signal detection
Quality Assurance and Safety of Medicines
Medication Safety Dr. Kanar Hidayat
Pharmacovigilance (PV)
68.3 million errors (28% of total) cause moderate or serious harm
Pharmacovigilance & Adverse Drug Reactions Dr. Habab Khalid Elkheir
Pharmacy practice experience I
Medicines Safety Mary R. Couper
Essentials of Good Pain Care: A Team-Based Approach
Medication Safety Dr. Kanar Hidayat
Quality Assurance and Safety of Medicines
8 Medication Errors and Prevention.
Pharmacovigilance.
Presentation transcript:

In the early 1900 s Paul Ehrlich described an ideal drug as a magic bullet. magic bullet. Such a drug would be aimed precisely at a disease site and would not harm healthy tissues. What is an ideal drug?

12/24/2015 Risk No medicinal product is entirely or absolutely safe for all people, in all places, at all times. We must always live with some measure of uncertainty.

We Must Always Ask: Do the potential benefits outweigh the potential risks for this individual? ACHP

Adverse Drug Reaction WHO definition: Any response to a drug which is Noxious and Unintended, and which occurs at doses used in man for prophylaxis, diagnosis or treatment.

تعريف : مطابق تعريف WHO عارضه نا خواسته دارويی عبارتست از : هرگونه پاسخ ناخواسته وزيان آور که در مقادير مصرف معمول دارو جهت تشخيص، پيشگيری و درمان بيماری ايجاد شود.

History of drug safety after thalidomide eradication  1961 : Dr William McBride (Australia)( thalidomide 4000 cases)  1964 : UK started “yellow cards” system  1968 : start of WHO Programme for International Drug Monitoring

Why Should We Learn about Adverse Drug Reactions (ADR)?  Over 2 MILLION serious ADRs yearly  100,000 DEATHS yearly  6.7% of hospitalized patients have an ADR with a fatality of 0.32, Ref: U.S. Food and Drug Administration. Center for Drug Evaluation and Research

Costs Associated with ADRs  $ 136 BILLION yearly (related to morbidity and mortality)  Greater than total costs of cardiovascular or diabetic care.  Mean length of stay, cost and mortality ADR patients are DOUBLE that for control group of patients without ADR.  ADRs cause 1 out of 5 injuries or deaths per year to hospitalized patients. Ref: U.S. Food and Drug Administration. Center for Drug Evaluation and Research

ADR has financial and social effects: 1- Unreliability on manufacturer 2- Unreliability on health system (Physician, Pharmacist & Nurse) 3- Unreliability on governments in saving the social safety 4- Causing mortality & morbidity

So many prescriptions!

 Tow-thirds of patients visits result in a prescription  2.8 BILLION outpatients prescriptions were filled in the year 2000 (about 10 prescriptions per person in the U.S.)  ADRs increase exponentially with 4 or more medications Ref: U.S. Food and Drug Administration. Center for Drug Evaluation and Research

Who might get an ADR? Anyone who takes a medicine –Differential diagnosis should include the possibility of an ADR if the patient is taking any form of medication

Who is most at risk from ADRs? Patients who; are young, or old or female are taking multiple therapies –50% of patients on 5 drugs or more have more than one medical problem have a history of allergy or a previous reaction to drugs

Older Adults and Medications Older adults make up 13% of population Account for: –About 30% of prescribed medications –About 40% of over-the-counter medications At least 90% take at least one prescription medication 12% use ten or more per week ACHP

How Knowledge About ADRs Is Created? 1-Animal experiments 2- Clinical trials 3- Epidemiological methods  Spontaneous reporting  Cohort studies  Case-control studies

Limitations of Clinical Trials  Limited size  Narrow population  Narrow indications  Short duration Ref: J. Russell May. Adverse drug Reactions and interaction, In: Pharmacotherapy, A pathophysiologic Approach. 1997, Appleton & Lange.

Drug Development

How many patients one needs to treat to see with high probability the reaction?  Pre-marketing studies are carried out in limited number of patients: “The law of three” –In order to detect for sure SAE that occurs as 1 event per 2000 patients treated we need to treat 6000 patientsfor 1 case 9600 patientsfor 2 cases patientsfor 3 cases The number of patients involved in pre-marketing studies has been increasing but is still limited in comparison with the exposure to the drug in post-marketing phase

Some drugs cause serious ADRs at very low frequencies  bromfenac hepatotoxicity 1 in 20,000 patients, removed from the market in 1998, less than 1 year after it was introduced). Ref: U.S. Food and Drug Administration. Center for Drug Evaluation and Research

 Assessment the quality of medications  Assessment of drug safety  Detection of occurrence rate of ADR  Decreasing the risk of occurrence of adverse events

Spontaneous Reporting Large population All medicines Hospital and out-patient care Long perspective Patient analysis possible Non-interventional Cheap

Examples of product recalls due to toxicity MedicineYear Thalidomide 1965 Practolol1975 Clioquinol1970 Benoxaprofen 1982 Terfenadine1997 Rofecoxib2004 Veralipride2007 Examples of serious and unexpected adverse events leading to withdrawal of medicine Phocomelia Sclerosing peritonitis Subacute nephropathy Nephrotoxicity, cholestatic jaundice Torsade de pointes Cardiovascular effects Anxiety, depression, movement disorders

Pharmaco - Vigilance Pharmaco = medicine Vigilare = to watch –alert watchfulness –forbearance of sleep; wakefulness –watchfulness in respect of danger; care; caution; circumspection –the process of paying close and continuous attention

Detection, Assessment & Prevention of ADRs in Human. Ref: World Health Organization.

فارماکوويژيلانس به تمام شيوه وروش های ارزيابی و پيشگيری از ADRs گويند. شناسايی ، ارزيابی ، گزارش عوارض ناخواسته دارويی و پيشگيری از وقوع آنها در انسان رافارماکوويژيلانس گويند.

Pharmacovigilance Major Aims Early detection of unknown reactions and interactions Detection of increase in frequency Identification of risk factors Quantifying risks Preventing patients from being affected unnecessarily RATIONAL AND SAFE USE OF DRUGS Ref: World Health organization.

The ultimate goal of pharmacovigilance is improving pharmacotherapy Ref:World Health Organization

Case #11: 34 yo female with DM, Hypertension, depression and recent UTI, taking metformin, insulin, lisinopril, paxil and ciprofloxacin. Presents with severe calf pain and difficulty with plantar flexion What is the most likely cause? A)Peroneal Nerve Palsy B)Diabetic Neuropathy C)Transient ischemia event D)Achilles Tendon Rupture

Case #11 (cont). Which medication is the most likely cause? A)Metformin B)Lisinopril C)Paxil D)Ciprofloxacin E)Insulin

Achilles Tendon Rupture Thompson Test

Misconceptions about ADR Reporting  All serious ADRs are documented by the time a drug is marketed  About patient receiving multiple medications,it is difficult to determine if a drug is responsible for the ADR  ADRs should only be reported if absolutely certain  One reported case can’t make a different  Ref: U.S. Food and Drug Administration. Center for Drug Evaluation and Research

Countries with the best reporting rates generate: Over 200 reports per 1,000,000 inhibitants per year. Over 150 reports per 1000 physicians per year.

- International Vigilance Every healthcare professional in the world should be constantly alert for adverse effects or potentional new hazards and reporting them to their National Centers.

ADR جهت دریافت اطلاعیه های

SEND A REPORT SAVE A LIFE Dr. Goodarzian

The FDA Safety Information and Adverse Event Reporting Program: Safety alerts Recalls Withdrawals Important labeling changes Biologicals, Drugs, Dietary supplements MedWatch